UNSPSC 51162700: Decongestants, expectorants, and mucolytics

This classification denotes drugs that a) treat nasal passage inflammation, substances called decongestants; and/or b) increase mucous excretion, substances called expectorants and/or mucolytics, thus the term DECONGESTANTS, EXPECTORANTS, AND MUCOLYTICS.

UNSPSC 51162700 Decongestants, expectorants, and mucolytics is a Class code, but recent state and local solicitations tagged under it diverge sharply from its nominal scope—the two posted opportunities pursue naloxone and safe drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products broadly, neither of which align with decongestant or mucolytic medications. State and local governments use this code space to procure emergency-response and preventive-health pharmaceuticals, including opioid-overdose reversal agents and harm-reduction systems, as well as bulk generic pharmaceutical inventory for health departments and cooperative purchasing networks. Issuing bodies include county health departments, state procurement offices administering multistate cooperative purchasing vehicles, and regional health authorities. The scope spans both emergency-preparedness commodities and routine institutional pharmaceutical supply.

Recent activity concentrates in Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline and quarterly delivery to the Seminole County Community Health Building; the contract carries a two-year initial term with one-year renewal option and includes FEMA funding eligibility. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awards effective July 1, 2026; vendors must partner with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health 110/112, or Morris & Dickson) and comply with cGMP and Drug Supply Chain Security Act requirements. The code shows limited recent activity overall, and the mismatch between the nominal code scope and the actual work being bought signals either miscoding in the source data or a broader code application than its name suggests.